Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women
| dc.contributor.author | Phoolcharoen N. | |
| dc.contributor.author | Areeruk W. | |
| dc.contributor.author | Kantathavorn N. | |
| dc.contributor.author | Tiyayon J. | |
| dc.contributor.author | Chittithaworn S. | |
| dc.contributor.author | Wetcho T. | |
| dc.contributor.author | Satitniramai S. | |
| dc.contributor.author | Khomphaiboonkij U. | |
| dc.contributor.author | Pitakkarnkul S. | |
| dc.contributor.author | Termrungruanglert W. | |
| dc.contributor.author | Srisomboon J. | |
| dc.contributor.author | Tangjitgamol S. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2023-09-12T18:01:45Z | |
| dc.date.available | 2023-09-12T18:01:45Z | |
| dc.date.issued | 2023-09-04 | |
| dc.description.abstract | OBJECTIVE: We compared the performance of high-risk human papillomavirus (HPV) messenger RNA testing of physician- and self-collected specimens for detecting histological grade 2 or higher cervical intraepithelial neoplasia (CIN) among women who visited a colposcopy clinic in Thailand. METHODS: From January 2022 to April 2022, 500 women participated in this cross-sectional multicenter study; 494 had complete data and valid specimen results. The participants were women who attended any one of the 10 participating institutes' colposcopy clinics due to abnormal cytology, positive high-risk HPV testing, or for follow-up. Participants used a self-sampling Aptima Multitest Swab specimen collection kit to self-collect vaginal samples before physicians biopsied the cervix during the colposcopic examination. The self- and physician-collected specimens were tested for high-risk HPV messenger RNA using Aptima nucleic acid amplification assays. Cervical tissues were collected during colposcopic-directed biopsy from the most severe lesion or a random biopsy and endocervical curettage specimen if no lesion was detected. RESULTS: We detected high-risk HPV messenger RNA in 75.4% of self-collected specimens and 70.6% of physician-collected specimens. The prevalence of histological grade 2 or higher CIN from cervical histology was 25.1% (n=124). For self-collected specimens, the sensitivity and specificity of high-risk HPV messenger RNA for grade 2 or higher CIN were 87.0% (95% CI 79.7% to 92.4%; n=108) and 28.5% (95% CI 24.0% to 33.4%). For physician-collected specimens, the sensitivity and specificity of high-risk HPV messenger RNA for grade 2 or higher CIN were 90.2% (95% CI 83.6% to 94.9%; n=112) and 36.1% (95% CI 31.2% to 41.3%). CONCLUSIONS: Self-collected specimens for high-risk HPV messenger RNA testing demonstrated good sensitivity and negative predictive value for detecting grade 2 or higher CIN in Thai women attending the participating institutes' colposcopy clinics. Self-collected samples performed similarly to physician-collected ones. | |
| dc.identifier.citation | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Vol.33 No.9 (2023) , 1354-1358 | |
| dc.identifier.doi | 10.1136/ijgc-2023-004424 | |
| dc.identifier.eissn | 15251438 | |
| dc.identifier.pmid | 37612037 | |
| dc.identifier.scopus | 2-s2.0-85169848119 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/90004 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85169848119&origin=inward | |
| oaire.citation.endPage | 1358 | |
| oaire.citation.issue | 9 | |
| oaire.citation.startPage | 1354 | |
| oaire.citation.title | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | |
| oaire.citation.volume | 33 | |
| oairecerif.author.affiliation | Ramathibodi Hospital | |
| oairecerif.author.affiliation | National Cancer Institute Thailand | |
| oairecerif.author.affiliation | Chulabhorn Royal Academy | |
| oairecerif.author.affiliation | King Chulalongkorn Memorial Hospital | |
| oairecerif.author.affiliation | Vajira Hospital | |
| oairecerif.author.affiliation | Rajavithi Hospital | |
| oairecerif.author.affiliation | Chiang Mai University | |
| oairecerif.author.affiliation | Office of the Thai Gynecologic Cancer Society |
